What is Bristol-Myers Squibb's deferred tax assets?

Bristol-Myers Squibb (BMY) reported deferred tax assets of $5.18B in Q1 2026.

How has Bristol-Myers Squibb's deferred tax assets changed year-over-year?

Bristol-Myers Squibb's deferred tax assets increased by 29.5% year-over-year, from $4B to $5.18B.

What is the long-term trend for Bristol-Myers Squibb's deferred tax assets?

Over 5 years (2020 to 2025), Bristol-Myers Squibb's deferred tax assets has grown at a 35.9% compound annual growth rate (CAGR), from $1.16B to $5.38B.

What does deferred tax assets mean?

Future tax benefits resulting from timing differences between accounting and tax reporting.

Non-Current Assets

Deferred Tax Assets

Bristol-Myers Squibb Deferred Tax Assets decreased by 3.8% to $5.18B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 29.5%, from $4B to $5.18B. Over 5 years (FY 2020 to FY 2025), Deferred Tax Assets shows an upward trend with a 35.9% CAGR.

Analysis

StatementBalance Sheet Statement

SectionNon-Current Assets

CategoryRisk

SignalContext dependent

VolatilityModerate

First reportedQ4 2019

Last reportedQ1 2026Apr 30, 2026

How to read this metric

An increase may signal future tax savings, though it can also reflect past losses or specific accounting treatments of R&D expenses.

Detailed definition

These are assets created when a company's tax expense for financial reporting purposes exceeds the amount currently paya...

Peer comparison

Common in capital-intensive industries with significant R&D tax credits or historical tax loss carryforwards.

Metric ID: non_current_assets_deferred_income_tax_assets_net

Historical Data

20 periods

	Q2 '21	Q3 '21	Q4 '21	Q1 '22	Q2 '22	Q3 '22	Q4 '22	Q1 '23	Q2 '23	Q3 '23	Q4 '23	Q1 '24	Q2 '24	Q3 '24	Q4 '24	Q1 '25	Q2 '25	Q3 '25	Q4 '25	Q1 '26
Value	$650M	$684M	$1.44B	$1.42B	$1.34B	$1.33B	$1.34B	$1.32B	$1.57B	$1.51B	$2.77B	$2.72B	$3.32B	$3.61B	$4.24B	$4B	$4.65B	$4.96B	$5.38B	$5.18B
QoQ Change	—	+5.2%	+110.4%	-1.5%	-5.7%	-0.6%	+1.1%	-2.0%	+19.4%	-3.7%	+82.8%	-1.6%	+22.0%	+8.6%	+17.4%	-5.6%	+16.3%	+6.8%	+8.4%	-3.8%
YoY Change	—	—	—	—	+105.7%	+94.3%	-6.6%	-7.1%	+17.6%	+13.9%	+106.0%	+106.8%	+111.4%	+138.4%	+53.0%	+46.8%	+39.8%	+37.5%	+27.0%	+29.5%

Range$650M – $5.38B

CAGR+54.8%

Avg YoY Growth+57.1%

Median YoY Growth+43.3%

Deferred Tax Assets at Other Companies

Johnson & JohnsonJNJ View metric

IncyteINCY View metric

Gilead SciencesGILD View metric

Neurocrine BiosciencesNBIX View metric

ViatrisVTRS View metric

West Pharmaceutical ServicesWST View metric

Frequently Asked Questions

What is Bristol-Myers Squibb's deferred tax assets?: Bristol-Myers Squibb (BMY) reported deferred tax assets of $5.18B in Q1 2026.
How has Bristol-Myers Squibb's deferred tax assets changed year-over-year?: Bristol-Myers Squibb's deferred tax assets increased by 29.5% year-over-year, from $4B to $5.18B.
What is the long-term trend for Bristol-Myers Squibb's deferred tax assets?: Over 5 years (2020 to 2025), Bristol-Myers Squibb's deferred tax assets has grown at a 35.9% compound annual growth rate (CAGR), from $1.16B to $5.38B.
What does deferred tax assets mean?: Future tax benefits resulting from timing differences between accounting and tax reporting.